Xeris Biopharma Holdings (XERS) Net Income towards Common Stockholders (QoQ) (2020 - 2026)
Xeris Biopharma Holdings (XERS) Net Income towards Common Stockholders (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.41 Bn | 1.30 Bn | 72.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.84% |
| Dec 31, 2025 | 1,684.38% |
| Sep 30, 2025 | 132.21% |
| Jun 30, 2025 | 79.09% |
| Mar 31, 2025 | -80.32% |
| Dec 31, 2024 | 67.51% |
| Sep 30, 2024 | -4.89% |
| Jun 30, 2024 | 20.94% |
| Mar 31, 2024 | -41.75% |
| Dec 31, 2023 | -9.85% |
| Sep 30, 2023 | 38.57% |
| Jun 30, 2023 | -17.87% |
| Mar 31, 2023 | -30.19% |
| Dec 31, 2022 | 40.77% |
| Sep 30, 2022 | 16.63% |
| Jun 30, 2022 | 22.33% |
| Mar 31, 2022 | 33.62% |
| Dec 31, 2021 | -95.28% |
| Sep 30, 2021 | 5.47% |
| Jun 30, 2021 | -49.45% |